October 6, 2023

Dear Colleagues,

Earlier this week, I had the pleasure of having dinner with about 35 members of Sisters’ Journey. I was joined by five other Yale faculty members, all of whom are involved in breast cancer care or research. As described on their website, “Sisters’ Journey is a faith-based organization founded to ensure that no women should have to endure or experience the challenge of facing the obstacles that accompany the reality of being diagnosed with breast cancer alone.” The group, composed of women of color, includes individuals who are going through breast cancer treatment as well as many breast cancer survivors. They are joined by friends, relatives, and supporters. In total, there are over 300 members and roughly 65 who participate regularly. The women, who live in all parts of the state and beyond, come together every month to share “the 3 E’s – Encouragement, Education, and Empowerment.” Sisters’ Journey was founded in 1999 by Linda White-Epps, four years before she lost her life to breast cancer. Her daughter, Dawn White-Bracey, the current president of Sisters’ Journey, is committed to the cause and to carrying on her mother’s legacy.

I spent an evening with Sisters’ Journey earlier this year. I was moved by their commitment to help one another, and by the women’s descriptions of their own breast cancer stories... They told me about the challenges they faced as Black and Latine women with breast cancer…and the frustration they have felt knowing that outcomes for women of color are frequently far less favorable than for White women. They also talked about the problem of breast cancer in younger Black women, and the need to improve screening and awareness for Black women, particularly those who are under 50 years of age. I appreciated their questions–often probing and complex–and their willingness to challenge me on anything I said that did not resonate with them. One of the women this week said they were actually “going easy on me.” I have continued to think about that evening and their feedback.

Our dinner together was great. All six of us from the faculty listened to the stories that circulated around the tables. I was surprised by the large number of women who had been diagnosed with two separate cancers, often many years apart. We were humbled by the deep support that the Sisters’ Journey members shared with each other. As they went around the room and told us when they were diagnosed, I sensed that the presence of long-term survivors was a tremendous sign of hope for those still reeling from a recent diagnosis and dealing with the side effects and complications of treatment.

As cancer researchers, doctors, nurses, social workers, and providers of care, spending time with a far-reaching community group like Sisters’...
care, spending time with a far-reaching community group like Sisters’ Journey is eye-opening. Talking to women from Sisters’ Journey and similar organizations is essential as we think about what we want YCC and Smilow to be in the years ahead. With the encouragement of our colleagues in the Center for Community Engagement and Health Equity (CEHE), directed by Marcella Nunez-Smith, we will continue to reach out to the community, listen to our patients and others in the community, and adjust our approaches to care and research. If we are going to achieve outstanding and equitable care for every patient, we all need to be on the same team, rowing hard in the same direction, and aiming high.

Eric

Announcements

Endocrine Cancers Program Welcomes Dr. Adriana Ramirez
Adriana Ramirez, MD, MPH, joined Smilow Cancer Hospital and Yale Cancer Center as an Assistant Professor of Surgery (Endocrine Surgery). Dr. Ramirez attended the Medical University of South Carolina and completed her general surgery training, including a post-doctoral research fellowship, at the University of Virginia. During her training, she received a Master of Public Health from the Harvard T.H. Chan School of Public Health focused on health policy and systems analytics. Most recently, Dr. Ramirez completed an American Association of Endocrine Surgeons (AAES) fellowship in Endocrine Surgery through Emory University.

Dr. Ramirez cares for surgical patients with benign and malignant thyroid, parathyroid, and adrenal tumors. Her clinical and research interests are focused on identifying health disparities among vulnerable populations and eliminating inequities in access, care, and outcomes for endocrine surgical patients. She has served on multiple departmental, institutional, and national Diversity, Equity, and Inclusion committees. She and her team at the University of Virginia were the recipients of the Dr. Martin Luther King, Jr. Health System Award for embodiment of values and teachings in cultural competence, healthcare disparities, and in fostering an environment of inclusiveness. She is a member of the American Association of Endocrine Surgeons, the Latin Surgical Society, the American College of Surgeons, and the Association of Women Surgeons.

Sarah Schellhorn, MD, Appointed Regional Service Line Medical Director for Central Shoreline Region
Sarah Schellhorn, MD, Associate Professor of Medicine (Medical Oncology) will assume additional responsibilities for Smilow Cancer Hospital and the Regional Service Line for the Central Shoreline Region.

Smilow Shares with Primary Care: Genetic Testing & Early Onset Cancer

Smilow Cancer Hospital and Yale Cancer Center Recognized as Outstanding Oncology Program

Yale New Haven Health Check: Dr. Melanie Lynch - Breast Cancer Signs, Treatment and Prevention
Hospital as Chief Ambulatory Officer focused on improvements in ambulatory clinical operations across the Smilow system in partnership with nursing, physician, and administrative leaders. In this expanded role, Dr. Schellhorn will contribute to the development of enterprise-wide ambulatory clinic processes and operational metrics with a particular focus on enhancing access to cancer care services.

She will also assume the role of Regional Service Line Medical Director for the newly named “Central Shoreline Region” comprised of New Haven, North Haven, Guilford, and Orange. In this role, Dr. Schellhorn will dyad partner with Monica Fradkin, Regional Service Line Director for the Central Shoreline Region. They will be responsible for the multidisciplinary ambulatory planning and operations at these four Smilow clinical sites.

In her role as Regional Service Line Medical Director, Dr. Schellhorn will work with leaders in medical oncology, surgery, radiation oncology, as well as a range of other departments, including supportive care services, to oversee the coordinated growth and integration of multidisciplinary cancer care programs at these sites.

**Smilow Cancer Hospital at Waterford Celebrates 10 Years**

Yesterday evening, physicians, providers, and staff from Smilow Cancer Hospital at Waterford welcomed guests from Smilow Cancer Hospital, the Lawrence + Memorial Hospital, community physicians, and donors to celebrate a decade of cancer care in the community. The Waterford facility was funded through generous support of many southeastern Connecticut residents to help expand services at Lawrence + Memorial Hospital. Smilow Cancer Hospital began providing care at the facility in 2016, with medical oncology and radiation oncology, as well as many supportive care services.

**ASTRO and ESMO**

Yale Cancer Center faculty and trainees had an incredible showing at the American Society for Radiation Oncology (ASTRO) meeting earlier this week in San Diego. Later this month, several faculty will travel to Madrid, Spain for the European Society for Medical Oncology (ESMO) Congress. A full list of Yale Cancer Center participation for both meetings is below.

ASTRO  
ESMO

**Notables**

The first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden’s Cancer Moonshot, and the latest in a long line of grants from the National Cancer Institute (NCI) and other federal agencies, was awarded to Yale's Cancer Center this week. The grant will support the development of new cancer drugs and therapies, as well as the expansion of clinical trials for existing treatments. The center will also receive funding from the National Cancer Institute to support its ongoing research into the links between cancer and obesity, as well as the development of new drugs and therapies for patients with cancer.

**Cancer Drug Shortage Eases Slightly, but it’s Still ‘Living from Paycheck to Paycheck’**

The first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden’s Cancer Moonshot, and the latest in a long line of grants from the National Cancer Institute (NCI) and other federal agencies, was awarded to Yale's Cancer Center this week. The grant will support the development of new cancer drugs and therapies, as well as the expansion of clinical trials for existing treatments. The center will also receive funding from the National Cancer Institute to support its ongoing research into the links between cancer and obesity, as well as the development of new drugs and therapies for patients with cancer.

**Promising Treatment on the Horizon for Cancer-related Fatigue**

The first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden’s Cancer Moonshot, and the latest in a long line of grants from the National Cancer Institute (NCI) and other federal agencies, was awarded to Yale's Cancer Center this week. The grant will support the development of new cancer drugs and therapies, as well as the expansion of clinical trials for existing treatments. The center will also receive funding from the National Cancer Institute to support its ongoing research into the links between cancer and obesity, as well as the development of new drugs and therapies for patients with cancer.

**CT Researcher Creates Immunotherapy for Canine Cancer**

The first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden’s Cancer Moonshot, and the latest in a long line of grants from the National Cancer Institute (NCI) and other federal agencies, was awarded to Yale's Cancer Center this week. The grant will support the development of new cancer drugs and therapies, as well as the expansion of clinical trials for existing treatments. The center will also receive funding from the National Cancer Institute to support its ongoing research into the links between cancer and obesity, as well as the development of new drugs and therapies for patients with cancer.

**ASCO Review 2023**

The first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden’s Cancer Moonshot, and the latest in a long line of grants from the National Cancer Institute (NCI) and other federal agencies, was awarded to Yale's Cancer Center this week. The grant will support the development of new cancer drugs and therapies, as well as the expansion of clinical trials for existing treatments. The center will also receive funding from the National Cancer Institute to support its ongoing research into the links between cancer and obesity, as well as the development of new drugs and therapies for patients with cancer.
in the United States, which is an outgrowth of President Biden's Cancer Moonshot program, has been awarded to a team at Yale School of Medicine, Emory University, and the University of Georgia. The nearly $25 million award, titled “Curing the Uncurable via RNA Encoded Immunogene Tuning,” aims to train the immune system to better fight cancer and other diseases by educating specific immune cells with mRNA technology. Richard Edelson, MD, the Anthony N. Brady Professor of Dermatology and a former director of Yale Cancer Center, is a co-principal investigator on the project. Learn more

The National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) have renewed a $20 million grant for the Yale Tobacco Center of Regulatory Science (TCORS). The Yale center is led by Cancer Prevention and Control Research Program members and co-directors Suchitra Krishnan-Sarin, PhD, Albert E. Kent Professor of Psychiatry; and Stephanie O'Malley, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry. Learn more

Patricia LoRusso, DO, Professor of Medicine (Medical Oncology), Associate Cancer Center Director for Experimental Therapeutics, and Leader of the Early Phase Clinical Trials Division at Yale Cancer Center and Smilow Cancer Hospital, received the Association of American Cancer Institute’s (AACI) 2023 Distinguished Scientist Award. The AACI Distinguished Scientist Award was created in 2002 to recognize a major contributor to the field of cancer research. To accept the award, Dr. LoRusso presented a heartwarming and gripping personal account of her clinical research career at the AACI annual meeting. Dr. LoRusso was integrally involved in the early development of more than two dozen anti-cancer agents that are now FDA approved and has pioneered trial designs that have led to more efficient clinical drug development strategies.

Susan Gueble, MD, PhD, Assistant Professor of Therapeutic Radiology, is the recipient of a High-Risk, High-Reward National Institutes of Health (NIH) Director’s Early Independence Award. This award is for exceptional junior scientists bypassing postdoctoral training to launch independent research careers. The project that received funding through the NIH High-Risk, High-Reward Research Program is titled, “Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer.” Learn more

Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, Dermatology, and Medicine (Medical Oncology) and a member of the Cancer Immunology Research Program, has been named one of eight Fierce Pharma’s 50 Breakthrough honorees for his contributions to immune checkpoints.

Kiran Turaga, MD, MPH, Division Chief of Surgical Oncology, Assistant Medical Director, Clinical Trials Office, and a member of the Cancer Immunology Research Program, has recently presented at the New England Surgical Society on “Utility of Circulating Tumor DNA Assessments in Characterizing Recurrence Sites After Optimal Resection for Metastatic Colorectal Cancer” and shared a poster on “Addition of Bevacizumab to First-line Perioperative Systemic Therapy for Colorectal and Appendiceal Cancer with Peritoneal Metastases.” On November 14, Dr. Turaga will participate in The Lancet Oncology Commission Webinar on Global Cancer Surgery highlighting pragmatic solutions to improve cancer surgery outcomes worldwide. Learn more and register.
Yale University has recognized fourteen members of their faculty with Yale Faculty Innovation Awards. The recipients were honored for bringing their discoveries to market and launching Yale innovation into the world. Yale Cancer Center awardees include:

- Akiko Iwasaki, PhD, Sterling Professor of Immunobiology and Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology (Microbial Diseases); Investigator, Howard Hughes Medical Institute; Cancer Immunology Research Program member/Company: Xanadu Bio, Inc
- Mark Mamula, PhD, Professor of Medicine (Rheumatology); Cancer Immunology Research Program member/Company: Therajan, LL
- W. Mark Saltzman, PhD, Goizueta Foundation Professor of Biomedical Engineering and Professor of Cellular and Molecular Physiology and of Chemical Engineering; Developmental Therapeutics Research Program member/Company: Xanadu Bio, Inc
- Yossi Schlessinger, PhD, William H. Prusoff Professor of Pharmacology; Co-Director, Cancer Biology Institute; Cancer Signaling Networks Research Program member/Company: Atias
- Jiangbing Zhou, PhD, Professor of Neurosurgery; Developmental Therapeutics Research Program member/Company: Couragene, Inc

The Society of Clinical Research Associates (SOCRA) recently held its annual conference in Montreal. Representatives from the Yale Center for Clinical Investigation, Yale Cancer Center’s Clinical Trials Office (CTO), and Yale HRPP were highlighted and contributed to key moments from the conference. Jessica Rowe, the Director of Quality and Education at the CTO, assumed the role of SOCRA President, served as the Chairperson of the meeting, and presented at two individual sessions and the IRB and Informed Consent Pre-conference workshop. Laura Holtz, a Clinical Research Associate at the Yale Center for Clinical Investigation, took on the role of President-elect, moderated the Project Management track, presented at the IRB and Informed Consent Pre-conference workshop, and delivered a presentation during the Closing Plenary on the subject of leading a successful research program. Alyssa Gateman concluded her term on the Board of Directors, moderated and presented at the SOP Development and Implementation Pre-conference workshop, and moderated the GCP and Audit Preparedness track. Linda Coleman, HRPP Director, presented a session on “Decentralized Clinical Trials: Navigating Ethical, Regulatory, and Practical Considerations for Successful Planning and Implementation.” Kira Pavlik, the Clinical Operations Senior Assistant Director at YCC CTO, received a Special Recognition award as a finalist for her poster on "Filling the Gap: A Novel Approach to Training and Integrating Research Pharmacists with Clinical Research Teams.” Theresa Goddard, Assistant Director of Monitoring at YCCI, presented a poster on "Using Effort Tracking Data to Evaluate Budgeting and More Accurately Estimate the Monitoring Support Required for Investigator-Initiated Trials.” Laura Lynn and Matthew Piscatelli, both Quality Assurance Specialists at YCCI, presented a poster on "Utilizing a Single Point of Contact for Sponsor and Cooperative Group Audits."

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology) and a member of the Developmental Therapeutics Research Program, will present clinical outcomes of the investigator initiated clinical trial led by Pat LoRusso, DO, A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors, on October 13 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Chicago.
Therapeutics in Chicago.

Ash Alpert, MD, Instructor of Medicine (Hematology), recently presented at Missouri State University on “Ways through the Mazes of Modern Medical Ethics.” Today, Dr. Alpert will participate in a “Representation in Research” panel at the Science of Cancer Health Equity for SGM Communities Conference and present on community-driven approaches to collecting SOGI data. Dr. Alpert is also scheduled to participate in Conquer Cancer Foundation’s Scientific and Career Development Retreat in November, moderating a panel on “Drivers of Disparities in Oncology” with Robert Winn, MD, and Marjory Charlot, MD, MPH, MSc, as panelists.

Dhanpat Jain, MD, Professor of Pathology and of Medicine (Digestive Diseases) and Genomics, Genetics, and Epigenetics Research Program member, was invited by the Houston Society of Clinical Pathologists to present on “Liver Biopsy: a diagnostic approach.” Dr. Jain also served as moderator for Joint Symposium ECP & Hans Popper Hepatopathology Society on “Morphomolecular-Driven Management of Liver Tumors” at the European Congress of Pathology, Dublin, Ireland and also presented on “Vascular Disorders of the Liver.”

Haris Mirza, MBBS, PhD, Instructor in Pathology, has been awarded a Clinical Scientist Research Career Development Award by the National Cancer Institute (NCI). The award provides support to clinician-scientists for intensive investigation and career development activities in cancer-focused research. The five-year award, titled “Immune Control of Oncogene Selection in Pre-neoplastic Colon,” will allow him to investigate the role of the immune system in colon cancer initiation.

Center for Community Engagement and Health Equity (CEHE)

Community Advisory Board
Yale Cancer Center’s Community Advisory Board (CAB) meets the first Tuesday of every month at 12:30pm. This engaged group of Connecticut residents are tasked with ensuring diverse and representative community voices guide YCC’s priorities and programming. YCC Investigators who would like to consult with the CAB may sign up for a presentation slot during one of the monthly meetings. Research at any stage of development may be presented for feedback. For more information please contact Erin Singleton.

Community Research Fellows
The Community Research Fellows program held their final celebration for the third cohort of Yale Cancer Center Fellows on September 12th at Southern Connecticut State University. This program, led by the Community Alliance for Research and Engagement (CARE), is developing a network of

Breast Cancer Awareness Month is a time to reflect on the women and men who are impacted by breast cancer. According to the National Breast Cancer Foundation, this year an estimated 297,790 women and 2,800 men will be diagnosed with invasive breast cancer. When caught early, the 5-year relative survival rate is 99%. Thanks to advances in early detection and treatment methods, survival rates have significantly increased in recent years; there are currently more than 3.8 million breast cancer survivors in the United States.

Throughout the month of October, we will share information from the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, educational programs, and support for our patients and their families.

Recently on Yale Cancer Answers in honor of October’s Liver Cancer Awareness Month, medical oncologist Dr. Stacey Stein discusses the care of patients with advanced liver cancer and new clinical trials that are available. Listen on Connecticut Public Radio or download our podcast from iTunes.
developing a network of community stakeholders in the New Haven, Bridgeport, and Waterbury areas who are equipped to partner with YCC investigators to bring a community perspective to cancer research. If you are an investigator interested in learning more about being paired with Community Research Fellows in the 2024 Cohort please reach out to Erin Singleton.

Survey on Clinical Trial Diversity
The Early Phase Clinical Trial Program and CEHE want to better understand barriers to early phase trial diversity within our system. Please help by taking ~7 minutes to complete a survey to understand Smilow provider perspectives. You can choose a $25 gift card or a donation on your behalf to a local food pantry or cancer support organization (up to $8,000) for your time. Please click here to complete the survey.

Employee Profile: Danielle DiBianco

Danielle DiBianco spent ten years working in healthcare, including at Yale New Haven Hospital, before joining the NP8 Multispecialty Clinic at Smilow Cancer Hospital. As someone who thrives on being busy, Danielle holds two roles on the floor: Front Desk Associate and Medical Assistant, and enjoys the experience of working on the front and back of the floor.

Danielle works each position on alternating days. While at the Front Desk, she checks in a near constant flow of patients, answers phones, provides directions to patients, codes incoming faxes, and assists the answering service. As a Medical Assistant, she brings patients to exam rooms, takes vitals, and reviews their concerns in preparation for their physician. As an outpatient oncology floor, the clinic has a steady flow of patients and is dedicated to caring for patients who often arrive nervous and scared. Always with a friendly face, Danielle takes time to talk with each patient, help them settle in and feel more comfortable, and tries to reduce their anxiety, re-emphasizing that they are in a wonderful place and will receive great care.

Working in the front and back of the clinic affords Danielle a lot of time to interact and establish relationships with patients and their families, a key factor that led her to pursue a career in healthcare. Her grandmother was a cancer survivor and went through radiation therapy, and her father is a retired firefighter, so she knew from an early age this was a career she was destined for.

The dual roles also give Danielle the opportunity to understand workflow and provide suggestions for improvements. She serves on the Local 34 Smilow Cancer Committee, where the group discusses system updates and how

Last week, leaders from Yale Cancer Center and Smilow Cancer Hospital and members of the Center for Thoracic Cancers traveled to New York City to attend the Lung Cancer Research Foundation Evening of Innovation gala honoring our very own Katerina Politi, PhD!

Dr. Politi was recognized for her academic accomplishments, leadership of her research lab at Yale, scientific advancements, and her volunteer roles. Dr. Politi has served as a mentor to innumerable scientists and is an inspiration to many in the lung cancer community. Congratulations!

Gean Brown, MSN, RN, OCN, CNML, Clinical Program Manager at Smilow Cancer Hospital at Trumbull and Bridgeport, shared information on lung cancer screening and presented Smilow Challenge Coins to veterans at the CT Department of Veterans Affairs annual STAND DOWN event in Bridgeport last week.
Cancer Committee, where the group discusses system updates and how operations can improve. Donna Durmazlar, Manager of Clinical Operations on NP8, says, “Danielle is always willing to help, and the patients absolutely love her!”

“Danielle consistently goes above and beyond for patients and her team,” says Rosy Cruz, Practice Administrator at Smilow Cancer Hospital. “She often floats from front desk to medical assistant responsibilities with ease, and her passion for our Health System’s values is seen and felt by everyone she encounters. Thank you, Danielle, for everything you do.”

Recent Publications


It can be overwhelming for parents grappling with a diagnosis of cancer in a child, especially when compounded with fear, work obligations, and balancing the feelings and needs of other children in the family. In a Q&A for Childhood Cancer Awareness Month, Asher Marks, MD, Associate Professor of Pediatrics (Hematology/Oncology) shares this advice to parents of his young patients: “Lean on us. We are here for you and have resources to help the entire family through this difficult time.”

Denise Paci, RN, is an exceptional nurse, a true role model, and a #SmilowStar. Every day she continues to excel in her role as a practice nurse and provides excellent care to her patients and their families. Denise goes above and beyond to ensure that each of her patients receives the highest-quality care and she does so with unconditional compassion. One recent example of her extreme dedication involved what started off as a simple prior authorization but then turned into a much more complex situation. Denise persevered for an entire week to ensure the patient received the necessary medication. Her compassionate heart is easily shown through every interaction with both her patients and her peers. We could not be more grateful to have such a valuable nurse on our team at Smilow Trumbull and Fairfield.
Funding and Award Opportunities

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)
This NOFO supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the NOFO solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

Application Deadline: October 13, 2023

Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1)
Through this non-competitive single source cooperative agreement NOFO, the NCI solicits an application from the Public Health Institute with the intent to support a non-competitive single-source agreement with the PEP-CTN.

Application Deadline: October 13, 2023

A #CancerMoonshot Award will be used by a @YaleCancer team led by co-PI Dr. Richard Edelson for research looking to harness the natural immune system to fight against #Cancer, #Lupus, and emerging infections.

@AneesChagpar will present "Negotiation 101: How to grow the pie and get your fair share" at the Women in NETs Luncheon, Friday, Oct. 6 at #NANETS2023.

Join us tomorrow, 10/6, at 9am in-person or online as our #GrandRounds kicks off with @DrRoyHerbstYale: "Moving from Palliation to Cure: Progress in the Treatment of Non-Small Cell Lung Cancer."

"We are moving now from age-based screening to risk-based screening as we understand that some women might be at increased risk for #breastcancer based upon family history or..."
Letter of Intent Deadline: October 15, 2023
Read More

2024 Innovation Awards Alex's Lemonade Stand Foundation
The Innovation Grant is designed to provide critical and significant seed funding for researchers with a novel approach to pediatric oncology scientific investigation. Proposals should be hypothesis-driven and innovative. This may represent a change in research direction and/or an innovative idea that moves away from an investigator’s prior research but for which a strong case is made for the potential impact on childhood cancers.
Letter of Intent Deadline: October 16, 2023
Read More

Lustgarten Foundation-AAACR Career Development Award for Pancreatic Cancer Research, In Honor of Ruth Bader Ginsburg
This award was established to honor the life and legacy of Justice Ginsburg, who worked tirelessly to advance gender equality, even while battling pancreatic cancer. The intent of this program is to support the development and diversity of talent working in pancreatic cancer research. This Award represents a joint effort to support the career advancement of a female scientist engaged in pancreatic cancer research.
Application Deadline: October 16, 2023
Read More

Lustgarten Foundation-AAACR Career Development Award for Pancreatic Cancer Research, In Honor of John Robert Lewis
This award was established to honor the life and legacy of Representative Lewis, who worked tirelessly to advance the civil rights of all Americans, even while battling pancreatic cancer. The intent of this program is to support the development and diversity of talent working in pancreatic cancer research. Eligibility is limited to members of racial or ethnic groups that have been shown to be underrepresented in the cancer related sciences workforce.
Application Deadline: October 16, 2023
Read More

ASCO Conquer Cancer Career Development Award
The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects.
Application Deadline: October 19, 2023
Read More

WHRY Pilot Project Program Funding
Proposals sought: Those that advance our understanding of the health of women and/or the influence of sex and gender on health
Funding opportunities:
Annual Pilot Project Award ($35,000 max) for research designed to meet a clear need in advancing the health of women.
The Wendy U. & Thomas C. Naratil Pioneer Award ($50,000 max) for highly inventive, new research on the health of women designed to achieve a breakthrough, or ongoing research in which funding is needed to achieve a discovery.
Community-Based Research Awards (up to $35,000) for data-driven community-based research designed to advance the health of women as a pathway to economic and social mobility.
Letter of Intent Deadline: Thursday, October 19, 2023
Read More

This morning at 10:30am PDT/1:30pm EST, Dr. Daniel Hicks will present a poster on the impact of #HeadAndNeckCancer treatment on #CD4 T cell decline/recovery in people with #HIV

Today at #ASTRO23, join @SanjayAnejaMD for an education session on the ethical and legal implications of #AI in medical practice at 8am PDT/11am EST.

A new study from @RachelPerryLab1 + led by Dr. Xinyi Zhang found that a metabolism-targeting drug helped alleviate cancer-related fatigue in mice w/o interfering with treatments for #cancer.

Today at #ASTRO23, Dr. Meriem Moktech @MMokhtechMD is presenting on residency recruitment bias during a joint session between @ASTRO_org and @RadOncPDs this afternoon at 4:13pm PDT/7:13pm EST.

Congratulations to @SusanGueble named today as a recipient of an @NIH Director's High-Risk, High-Reward Early Independence Award!

Dr. Bethel Adefres @beteldawit is presenting research on the relationship between the dose to the recto-vaginal reference point and vaginal stenosis in pts with #cervicalcancer in a poster session today at 5:15pm PDT/8:15pm EST.

Congratulations to Dr. Rachel Greenup @GreenupRachel, named co-director of the Center for Breast Cancer @SmilowCancer

Today at 2:30pm PDT/5:30pm EST, Sajid Hossain presents a poster on MRI imaging biomarkers for #ProstateCancer using #deeplearning.

This afternoon #ASTRO23 at 12:45pm PDT/3:45pm EST, Dr. Kevin Du presents a poster on the ethical and legal implications of #AI in medical practice at 8am PDT/11am EST.

#ProstateCancer
#HeadAndNeckCancer
#cervicalcancer
#breastcancer based upon family history or other personal risk factors." Dr. Melanie Lynch.
The Pershing Square Sohn Prize for Young Investigators in Cancer Research provides greater New York City area-based early career scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking. As of 2023, Prize winners each receive $250,000 a year for three years, totaling $750,000. At least six prizes are awarded annually.

Letter of Intent Due: October 30, 2023
Read More

The Pershing Square Sohn Cancer Research Alliance 2024 Prize for Rising Leaders in Cancer Research
A prize of $250,000 per year for three years will be awarded to at least six New York City area-based scientists. The Prize empowers researchers to pursue novel, high-risk/high-reward cancer research at a stage when traditional funding is lacking. Applicants must have between two and six years of experience running their own laboratories by the award start date (July 2024), hold a PhD, MD, or MD-PhD (or degree equivalent), and be affiliated with a research institution in the greater New York City area.

Letter of Intent Due: October 30, 2023
Read More

Leveraging Social Networks to Promote Widespread Individual Behavior Change (R01)
The purpose of this NOFO is to invite basic observational or experimental behavioral and/or social science R01 applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. Research supported through this NOFO will examine at least two levels of analysis: interpersonal processes and social network characteristics.

Application Deadline: November 3, 2023
Read More

Investigator-Initiated Research in Genomics and Health Equity (R01)
The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations.

Application Deadline: November 8, 2023
Read More

ACRA for Diversity and Inclusion in Breast Cancer Research
This award is designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to mid-career investigators who are members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research, and who wish to conduct original breast cancer research not currently funded.

Application Deadline: November 16, 2023
Read More

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21)
The purpose of this FOA is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

Application Deadline: November 17, 2023
Read More

Early-Stage Development of Informatics Technologies for Cancer Research
Kevin Du presents a poster featuring research on racial disparities using SBRT for patients with liver cancer.

Congratulations to @DaveJCarlson as he officially receives the #FASTRO designation this morning at the FASTRO Awards Ceremony!
Research and Management (U01)
The purpose of this FOA is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Application Deadline:** November 17, 2023

Advanced Development of Informatics Technologies for Cancer Research and Management (U24)
The purpose of this FOA is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities.

**Application Deadline:** November 17, 2023

Sustained Support for Informatics Technologies for Cancer Research and Management (U24)
The purpose of this FOA is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Application Deadline:** November 17, 2023

Lion Heart Fund for Cancer Research Grant Opportunity
Yale investigators are encouraged to submit proposals of innovative, high-potential projects requiring pilot funding. Projects may be in any area of breast cancer research – basic, translational, clinical, outcomes and population science are all welcomed from any discipline or group of disciplines.

Funding will be $50,000 for a one-year project. The number of projects funded will depend on the amount of funds raised the preceding year but is estimated at two (2) projects for the 2024 cycle.

**Proposal Deadline:** November 27, 2023. Any questions, please reach out to David Stern

2024 ACS IRG Pilot Grant
The purpose of this grant is to provide pilot funds (up to $40,000 total for one year) for the initiation of promising new projects or novel ideas by Yale Assistant Professors so that they can obtain preliminary results to enable them to compete successfully for national cancer research grants. These grants will support all potential areas of cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research.

**Internal Submission Deadline:** November 27, 2023

Understanding and Mitigating Health Disparities experienced by People with Disabilities caused by Ableism (R01 Clinical Trial Optional)
The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health care setting level, is encouraged.

**Application Deadline:** November 17, 2023

10th Annual The Endoscopy Course
**October 13-14, 7:00 AM**
1 Goat Island Rd, Newport RI
**Cases and Controversies in Endoscopy**
Speakers TBA

Nephrology Noon Conference
**October 13, 2023 12:00 PM**
Zoom
**Basic Science of AKI**
Lloyd Cantley

Digestive Diseases Pathophysiology Seminar
**October 13, 2023 1:00 PM**
Zoom
**Liver Malignancies (HCC & CCA)**
Mario Strazzabosco

Patient & Family Conference Aplastic Anemia
**October 14, 2023 7:30 AM**
55 Park St Auditorium
**MDS – Aplastic Anemia – PNH**
Mina Xu, MD; Nikolai Podoltsev, MD, PhD
health systems level to mitigate adverse health effects of ableism are high

**Application Deadline:** November 29, 2023

Read More

**Center for Exposome Research Coordination to Accelerate Precision Environmental Health (U24)**

This NOFO solicits applications for establishing a Center for Exposome Research Coordination (CERC) that will serve the broad biomedical research community by coordinating and advancing exposome research to accelerate precision environmental health. The CERC will engage existing and ongoing exposome initiatives around the globe to promote methodological advancement and best practices, provide training and education, and foster national and international collaborations.

**Application Deadline:** November 30, 2023

Read More

**Rising Tide Foundation for Clinical Cancer Research**

RTFCCR's primary consideration in granting support is given to innovative, patient-centered clinical research. RTFCCR funds clinical trials within the focus areas: Improved Patients Outcomes; Science of Early Detection and Intervention; Advancing Cancer Research in Underserved Areas

**Letter of Intent Due:** December 5, 2023

Read More

**Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01)**

The purpose of this NOFO is to invite applications for a Research Project (U01) that will utilize health communication research to better understand the impact that messaging about the continuum of risk for tobacco products may have on various segments of the population.

**Application Deadline:** December 6, 2023

Read More

**Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01)**

The purpose of this NOFO is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

**Application Deadline:** December 15, 2023

Read More

Mina Xu, MD; Nikolai Podoltsev, MD, PhD; Lourdes Mendez, MD, PhD

Learn More

**Yale Cancer Answers**

October 15, 2023

WNPR90.5

*The Development of Anti-Cancer Vaccines*

Richard L Edelson, MD

Learn More

**Yale Cell Biology Seminar Series**

October 17, 2023 1:00 PM

The Anlyan Center, TAC N107-1 300 Cedar St

New Haven

*Mechanoepigeneitic Engineering of Cell Fate*

Song Li, PhD, University of California, Los Angeles

Learn More

**Smilow Shares**

October 17, 2023 7:00 PM

Zoom

*Breast Cancer Awareness*

Maryam Lustberg, Md, MPH, Daniel O’Neil, MD, MPH, Sharynn Hall, MD, PhD

Learn More

**Pharmacology Seminar Series**

October 19, 2023 12:30 PM

Brady Memorial Laboratory, 310 Cedar St

New Haven

*Exploring and Exploiting the Spatial Constraints of Protein Kinase Signaling*

John Scott, University of Washington

Learn More

**2023 Digestive Health Virtual CME Series**

October 19, 2023 5:00 PM

Zoom

*Third Thursdays Trust your Gut*

Walter Longo; Ritche Hao; Haddon Pantel; Bauer Sumpio; Xavier Llor; Nitu Kashyap; Myron Brand; Darrick Li; Kevin Schuster; Melanie Sion; Scott Roberts; Jill Banatoski; Loren Laine; Anil Nagar; Thiruvengadam Muniraj; Amit Khanna; Ira Leeds; Joseph Lim; Maricar Malinis; Cattie Antunes; Katherine M. Reeve, MD; Andrew Duffy; Andrew Kenler; Guadalupe Garcia-Tsao

Learn More

**Surgery Grand Rounds**

October 20, 2023 7:30 AM

Fitkin Memorial Pavilion Auditorium, 789 Howard Ave

New Haven
Share your news!
Please submit your recent publications, awards, and grant announcements to:

**Renee Gaudette**
Director, Public Affairs and Communications

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

Unsubscribe renee.gaudette@yale.edu
Update Profile | Constant Contact Data Notice

Sent by renee.gaudette@yale.edu powered by Constant Contact

Try email marketing for free today!